To better understand the mechanism of action of gemfibrozil on plasma triglycerides, lipoprotein lipase (LPL) concentration was measured in adipose tissue and muscle of 16 hypertriglyceridemic patients before and after treatment with gemfibrozil for 6 weeks. The patients were divided into three groups based on clinical criteria as follows: group 1, hypertriglyceridemia without secondary factors; group 2, hypertriglyceridemia with diabetes; and group 3, hypertriglyceridemia with renal insufficiency. LPL activity, immunoreactive mass, synthetic rate, and mRNA levels were measured in the adipose tissue samples, and LPL activity and mass in the muscle samples. Serum triglyceride levels were decreased by 46% by gemfibrozil, and patients demonstrated no change in diet, weight, or glycohemoglobin during the 6 weeks of treatment. Despite the decrease of blood triglyceride levels, there was no significant change in any measure of LPL either in adipose tissue or muscle. Although several patients demonstrated increases in muscle LPL activity, these changes were inconsistent and not statistically significant. Because there was no significant change in LPL, we conclude that gemfibrozil in these patients decreased circulating triglyceride levels predominantly by decreasing hepatic very-low-density lipoprotein (VLDL) secretion.
|Number of pages||6|
|Journal||Metabolism: Clinical and Experimental|
|State||Published - Nov 1993|
Bibliographical noteFunding Information:
From the Department of Medicine, Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA. Submitted November 7, 1992; accepted Januaty 27. 1993. Supported by a grantf rom Parke-Davis/ Warner Lambert. A Career Development Award from the Juvenile Diabetes Foundation (J.M. 0. J, and National institutes of Health Grant No. DK 39176 (P.A. K. ). Conducted during the tenure of an Established Investigatorship from the American Heart Association (P.A.K.). Address reprint requests to Philip A. Kern, MD, Division of Endocrinology, Becker 131. Cedars-Sinai Medical Center, 8700 Bev-erlv Blvd, Los Angeles, CA 90048. Copyright 0 1993 by W.B. Saunders Company 0026-049519314211-0018$03.00/0
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism